MADRID, 1 Nov. (EUROPA PRESS) –
The American laboratory Pfizer recorded an attributed net profit of 8,608 million dollars (8,658 million euros) during the third quarter of the year, which corresponds to an improvement of 6% compared to the same period of the previous year, according to the report of results of the company published this Tuesday, in which the company has updated its billing projections upwards.
The company’s turnover fell by 6% in the third quarter, to 22,638 million dollars (22,762 million euros). However, in the accumulated period of the year, sales have increased by 32%, reaching 76,040 million dollars (76,458 million euros).
In this context, the company has improved its prospects for this year, now projecting a lower income range of 99,500-102,000 million dollars (100,122-102,638 million euros) for the entire year of 2022. The improvement, the company explained , is due to better operating prospects and a positive effect on cross-currency exchange rates.
The vaccine business registered sales worth 15,846 million dollars (15,933 million euros) between July and September, 5% less, while the hospital area registered revenues of 3,404 million (3,424 million euros), 9% less. The oncology area, on its side, invoiced 3,070 million dollars (3,088 million euros), in line with the previous year after falling only 0.4%.
In the January-September period, the net profit of the American pharmaceutical company reached 26,378 million dollars (26,547 million euros), which implies an improvement of 42% compared to the same period of the previous year.
